Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483917 | 0.87 | HTR6 (0.48) | DRD2METPIK3C3HTR6THRB | |
| SCHEMBL4494776 | 0.84 | HTR6 (0.58) | METPIK3C3HTR6 | |
| SCHEMBL4478910 | 0.80 | HTR6 (0.44) | DRD2METDRD4HTR6THRB | |
| SCHEMBL5879490 | 0.78 | DRD2 (0.49) | DRD2DRD4HTR6THRBL3MBTL1 | |
| SCHEMBL4484018 | 0.77 | HTR6 (0.48) | DRD2DRD4HTR6HTR2A | |
| SCHEMBL4476828 | 0.76 | CA12 (0.52) | DRD2METDRD4HTR6HTR2A | |
| SCHEMBL4485307 | 0.74 | HTR6 (0.49) | METPIK3C3HTR6KDM4EALDH1A1 | |
| SCHEMBL4482698 | 0.72 | DRD2 (0.46) | DRD2HTR6MAPK1 | |
| SCHEMBL3956975 | 0.72 | DRD2 (0.54) | DRD2DRD4HTR6L3MBTL1KDM4E | |
| SCHEMBL16913783 | 0.71 | MET (0.62) | METPIK3C3HTR6TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | claimed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | claimed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | DRD2 120/4885MET 1084/4885PIK3C3 3771/4885 |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | DRD2 108/4885MET 1152/4885PIK3C3 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.